The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 52 | 1.2x | 20.1x | Near average | |
Growth | 49 | -82.8% | 5.6% | Near average | |
Quality | 54 | 120.2% | 7.6% | Near average | |
Safety | 25 | 0.5x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Coherus Oncology, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Coherus Oncology, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The analyst outlook for Coherus has experienced sharp divergence as the number of following analysts decreased from 3 to 2, indicating a decline in research coverage. Although the average price target remained stable at $6.02, the significant gap between the high estimate ($11) and the low estimate ($1.05) reflects high uncertainty and ambiguity in estimating the stock's fair value compared to its current price.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.